Biopharma Partner Symposium 2024
第10回Genedata Biopharma Partner Symposiumより、イベントレポートをお届けします。
今回、250名を超える研究者やITのプロフェッショナルに参加いただきました。出席企業には、Pfizer・Novartis・AstraZeneca・AbbVie・GSK・Bayer・Janssen・Merck・Sanofi・Boehringer Ingelheim・Amgen・Gilead・Roche・Daiichi Sankyo・Novo Nordisk・UCB・Servier・Ferringなどの大手バイオファーマ企業、Genmab・Bicycle Therapeutics・Immaticsなどの実績あるバイオテクノロジー企業、さらにはSartorius・Sandoz・Novozymes・Charles RiverなどのCRO/CDMOが含まれます。
信頼と実績
Genedata Biopharma Platformは、多くの大手グローバルバイオファーマや先端バイオテックから信頼を受けているソリューションです。
製剤の種類やモダリティに関わらず、複雑なプロセスを自動化し、コストの大幅な削減、ワークフローの加速、そして総合的な生産性の改善を支援し続けています。
変革を支えるサービス
Genedataは多様なコンサルティングサービスならびにプロフェショナルサービスを提供しています。これらはプラットフォームの最適な設定や利用を円滑にし、オンプレミス（自社運用）あるいはクラウド（SaaS）にてベストプラクティスの採用を容易にします。
One of the reasons we chose Genedata was the platform’s process coverage. We required that the full diversity of Pfizer’s large-molecule processes and technologies be supported by one integrated system.
Genedata gives us automated, workflow-based processing and powerful visualizations—all of which enables our high-quality biomarker identification process.
During our initial deployment, we recorded quantifiable increases in productivity. The number of results posted to our data warehouse more than doubled, indicating that we could capture results from many more experiments, while the cost of running day-to-day operations decreased.
We are excited to implement the Genedata Biopharma Platform as a central integrated data backbone to streamline the capture, integration, democratization, and analysis of increasingly complex and diverse data types.
The Biologics Data Platform supports our scientists in a complex, multi-site environment by providing all the necessary information and tools to streamline the biologics lead generation and optimization process.
Genedata enables us to integrate a wide variety of complex data generated by novel experimental workflows so we can gain a holistic molecular understanding of production cells with the goal of developing high performing bioproduction processes.
We need to enhance our capacity to analyze large amounts of high-dimensional ‘omic data emerging from our rapidly growing number of translational and clinical research projects. We chose Genedata because it is the end-to-end enterprise software able to harmonize our dispersed data analysis pipelines.
We aimed to extend automation and further enhance the efficiency of our cell line, upstream and bioanalytical development operations, and quickly realized that Genedata addresses many of our requirements off-the-shelf, eliminating the need for expensive customization.
The Genedata platform is an important cornerstone in enhancing the analytical capabilities of our teams with cutting-edge digital technology.
Genedata gives all our R&D groups a central place to record and access TCR-related information in real time, along the end-to-end workflow.
To optimally handle the complex data, we need a centralized genome knowledge management and analysis solution that addresses the interdisciplinary challenges in next-generation biotechnology innovations. Genedata was our obvious choice.
Genedata provides comprehensive biologics data management functionality and the flexibility needed to support our proprietary antibody discovery processes and technology portfolio. And, it provides this functionality out-of-the-box, which saves valuable research time and money.
Markus Enzelberger, Ph.D.
Senior Vice President and Head of Discovery, Alliances and Technologies
We especially appreciated the high level of expertise and support provided by Genedata, which enabled us to optimize every stage of our analytical processes—while incorporating industry best practices—and quickly generate high-quality results.
Genedata tracks all biologics molecules from early discovery to development, and gives the UCB R&D organization central access to all relevant information on these molecules.
